Archive | Of Interest

Soluble PD-1 Is a Potential Biomarker in Metastatic Melanoma in Patients Treated With Autologous Vaccines

Research on programmed-death 1 (PD-1) found on T cells and its receptor, programmed-death ligand 1 (PD-L1), found in varying levels on tumor is a central topic in immunotherapy.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Single-Cell Level Variability May Help Predict Responses to BRAF Inhibitors in Melanoma

New targeted therapy options, such as BRAF and MEK inhibitors, offer advanced treatment for patients with melanoma; however, genetic variability often means that patients will have different therapeutic responses.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Enter the exosome: WVU researcher studies how cancer and immune cells communicate

Cells can’t text each other the way we can, but they can still communicate.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Moffitt Researchers Identify a Mechanism Controlling Tumor Cell Recognition by Immune Cells

TAMPA, Fla. – Immunotherapy has become a standard treatment approach for several types of cancer, including melanoma

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest